Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: A randomized, observer-blind, controlled study

Journal of Infectious Diseases

Volumn 210, Issue 9, 2014, Pages 1419-1430

  Roy Ghanta, Sumita ^a   Van Der Most, Robbert ^b   Li, Ping ^a   Vaughn, David W ^b  

^a GLAXOSMITHKLINE   (United States)

^b GSK   (Belgium)

Author keywords

A(H1N1)pdm09 vaccine; AS03; B cells; CD4+ T cells; HI antibody; Immune interference; Neutralizing antibody; Pandemic in fluenza; Plasmablasts; TIV

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; TRIVALENT SEASONAL INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; AORTA ANEURYSM; ARTHRALGIA; ARTICLE; BACKACHE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHOLELITHIASIS; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA VACCINATION; INJECTION SITE PAIN; LIVER FUNCTION TEST; MALE; MEMORY CELL; MYALGIA; NAUSEA; NORMAL HUMAN; PLASMABLAST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; UTERUS MYOMA; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; SINGLE BLIND PROCEDURE; YOUNG ADULT;

ADULT; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84922021761     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu284     Document Type: Article

References (37)

1. Jayaraman A, Pappas C, Raman R, et al. A single base-pair change in 2009 H1N1 hemagglutinin increases human receptor affi nity and leads to ef fi cient airborne viral transmission in ferrets. PLoS ONE 2011; 6:e17616.
2. World Health Organization. Pandemic H1N1 (2009) - update 112. Global Alert and Response Weekly Update, 2010. http://www.who.int/csr/don/2010-08-06/en?/index.html. Accessed 23 May 2013.
3. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the fi rst 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12:687-95.
4. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-13.
5. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché M-K, Denis M. Immune response after a single vaccination against 2009 in fl uenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375:41-8.
6. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 in fluenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35.
7. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic infl uenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8:650-8.
8. A-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51:668-77.
9. Roman F, Clément F, DewéW, et al. Effect on cellular and humoral immune responses of the AS03 Adjuvant System in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011; 18:835-43.
10. Andrews NJ, Walker WT, Finn A, et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic in fluenza vaccines. Vaccine 2011; 29:7913-9.
11. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster J-M. Immunogenicity and safety in adults of one dose of infl uenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740-5.
12. Peeters M, Regner S, Vaman T, Devaster J-M, Rombo L. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials. Vaccine 2012; 30:6483-91.
13. Huijskens E, Rossen J, Mulder P, et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against influenza A virus (H1N1) 2009 in a healthy population. Clin Vaccine Immunol 2011; 18:1401-5.
14. Van Damme P, Kafeja F, Bambure V, et al. Long-term persistence of humoral and cellular immune responses induced by an AS03A -adjuvanted H1N1 2009 in fl uenza vaccine: an open-label, randomized study in adults aged 18- 60 years and older. Hum Vaccin Immunother 2013; 9:1512-22.
15. Uno S, Kimachi K, Kei J, et al. Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial. Microbiol Immunol 2011; 55:783-9.
16. Wu J, Zhong X, Li CK, et al. Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal in fluenza vaccines in humans. Vaccine 2011; 29:1009-16.
17. Zhou Y, Ng DM, Seto WH, et al. Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine. PLoS One 2011; 6:e27169.
18. Choi YS, Baek YH, Kang W, et al. Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination. Clin Vaccine Immunol 2011; 18:1519-23.
19. Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010; 303:37-46.
20. Nolan T, Richmond PC, Formica NT, et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008; 26:6383-91.
21. A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849-57.
22. Kim JH, Skountzou I, Compans R, Jacob J. Original antigenic sin responses to influenza viruses. J Immunol 2009; 183:3294-301.
23. Fazekas de St Groth S, Webster RG. Disquisitions on original Antigenic Sin. I. Evidence in man. J Exp Med 1966; 124:331-45.
24. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high affinity human monoclonal antibodies against in fluenza virus. Nature 2008; 453:667-71.
25. Gulati U, Kumari K, WuW, KeitelWA, Air GM. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine 2005; 23:1414-25.
26. Kim JH, Davis WG, Sambhara S, Jacob J. Strategies to alleviate original antigenic sin responses to influenza viruses. Proc Natl Acad Sci U S A 2012; 109:13751-6.
27. Moris P, van der Most R, Leroux-Roels I, et al. H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443-54.
28. Khurana S, Chearwae W, Castellino F, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010; 2:15ra5.
29. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3:85ra48.
30. Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:2461-73.
31. Hehme NW, Künzel W, Petschke F, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002; 22:751-69.
32. European Agency for Proprietary Medicinal Products. Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/ CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products (CHMP), 2007.
33. US Food and Drug Administration. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. 2007.
34. Deenick EK, Ma CS. The regulation and role of T follicular helper cells in immunity. Immunology 2011; 134:361-7.
35. Treanor JJ, Campbell JD, Brady RC, et al. Rapid licensure of a new, inactivated infl uenza vaccine in the United States. Hum Vaccin 2005; 1:239-44.
36. Barker CI, Snape MD. Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis 2014; 14:227-38.
37. + T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 infl uenza A epitope in narcolepsy. Sci Transl Med 2013; 5:216ra176.